Critical Insights From Tandem Diabetes Care Analyst Ratings: What You Need To Know
In the latest quarter, 15 analysts provided ratings for Tandem Diabetes Care (NASDAQ:TNDM), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 6 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 4 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 5 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 2 | 0 | 0 |
Analysts have recently evaluated Tandem Diabetes Care and provided 12-month price targets. The average target is $48.8, accompanied by a high estimate of $75.00 and a low estimate of $31.00. Witnessing a positive shift, the current average has risen by 33.7% from the previous average price target of $36.50.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Tandem Diabetes Care among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Steven Lichtman | Oppenheimer | Raises | Outperform | $58.00 | $47.00 |
| Issie Kirby | Redburn Atlantic | Announces | Buy | $60.00 | - |
| Brooks O'Neil | Lake Street | Raises | Buy | $75.00 | $60.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $57.00 | $40.00 |
| Mathew Blackman | Stifel | Raises | Buy | $55.00 | $45.00 |
| Matt Miksic | Barclays | Raises | Overweight | $55.00 | $39.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $50.00 | $45.00 |
| Matt O'Brien | Piper Sandler | Raises | Overweight | $50.00 | $35.00 |
| Jeff Johnson | Baird | Raises | Neutral | $36.00 | $28.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $45.00 | $21.00 |
| Mike Kratky | Leerink Partners | Raises | Outperform | $45.00 | $34.00 |
| Mathew Blackman | Stifel | Raises | Buy | $40.00 | $37.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $38.00 | $31.00 |
| Mathew Blackman | Stifel | Raises | Buy | $37.00 | $24.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $31.00 | $25.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Tandem Diabetes Care compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Tandem Diabetes Care's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tandem Diabetes Care's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Tandem Diabetes Care analyst ratings.
Delving into Tandem Diabetes Care's Background
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Key Indicators: Tandem Diabetes Care's Financial Health
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Tandem Diabetes Care displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 13.16%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Tandem Diabetes Care's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -22.29%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Tandem Diabetes Care's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -15.35%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Tandem Diabetes Care's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.51%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.96, Tandem Diabetes Care faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.